---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-081126"
form_type: "8-K"
ticker: "ALGS"
cik: "0001799448"
company_name: "Aligos Therapeutics, Inc."
filed_at: "2022-03-22T23:59:59+00:00"
generated_at: "2026-06-26T21:05:38.042150+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Aligos discontinues hepatitis B drug ALG-020572 after patient hospitalized with ALT flare

## Summary
- Discontinued ALG-020572 (ASO for chronic hepatitis B) after one subject hospitalized and three others experienced ALT flares following 210 mg multiple dosing.
- Dosing in first CHB cohort of Study 401 stopped after serious adverse event (ALT increase, brief hospitalization).
- All four affected subjects improving; hospitalized subject discharged. No further details on safety provided.
- Cost savings from discontinuation to fund clinical and preclinical programs in CHB, NASH, and COVID-19.

## SEC filing metadata
- accession: 0001193125-22-081126
- form_type: 8-K
- ticker: ALGS
- cik: 0001799448
- company_name: Aligos Therapeutics, Inc.
- filed_at: 2022-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799448/000119312522081126/0001193125-22-081126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799448/000119312522081126/d320642d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-081126
- JSON: https://secwatch.observer/filing/0001193125-22-081126.json
- Plain text: https://secwatch.observer/filing/0001193125-22-081126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.